Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Barchart · 10/15 06:30

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024

Topline clinical data from SOL-1 are now expected in Q4 2025

Read more at globenewswire.com